Pfizer ties PD-1 drug to 32% bladder cancer risk reduction in mixed bag phase 3 as it misses secondaries
Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial. But the study fell short of a clean sweep of positive outcomes, with the Big Pharma finding no effect on overall survival and seeing a higher rate of serious adverse events in the PD-1 arm.
Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial. But the study fell short of a clean sweep of positive outcomes, with the Big Pharma finding no effect on overall survival and seeing a higher rate of serious adverse events in the PD-1 arm.
